{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:33:05Z","timestamp":1776169985954,"version":"3.50.1"},"reference-count":71,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Health Commission of Sichuan Province","award":["23LCYJ042"],"award-info":[{"award-number":["23LCYJ042"]}]},{"name":"Health Commission of Sichuan Province","award":["2021JDKP004"],"award-info":[{"award-number":["2021JDKP004"]}]},{"name":"Health Commission of Sichuan Province","award":["HX-H2206155"],"award-info":[{"award-number":["HX-H2206155"]}]},{"name":"Science and Technology Bureau of Sichuan Province","award":["23LCYJ042"],"award-info":[{"award-number":["23LCYJ042"]}]},{"name":"Science and Technology Bureau of Sichuan Province","award":["2021JDKP004"],"award-info":[{"award-number":["2021JDKP004"]}]},{"name":"Science and Technology Bureau of Sichuan Province","award":["HX-H2206155"],"award-info":[{"award-number":["HX-H2206155"]}]},{"name":"a grant investigating the effect and mechanism of secretory group derived from umbilical cord mesenchymal stem cells on chronic wound healing in Bama miniature pig with diabetes","award":["23LCYJ042"],"award-info":[{"award-number":["23LCYJ042"]}]},{"name":"a grant investigating the effect and mechanism of secretory group derived from umbilical cord mesenchymal stem cells on chronic wound healing in Bama miniature pig with diabetes","award":["2021JDKP004"],"award-info":[{"award-number":["2021JDKP004"]}]},{"name":"a grant investigating the effect and mechanism of secretory group derived from umbilical cord mesenchymal stem cells on chronic wound healing in Bama miniature pig with diabetes","award":["HX-H2206155"],"award-info":[{"award-number":["HX-H2206155"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Background: Several studies have shown that sodium-dependent glucose transporter 2 inhibitors can be used in the treatment of heart failure. This article summarized systematic reviews of sodium-dependent glucose transporter 2 inhibitors in the treatment of heart failure in order to evaluate efficacy and safety. Methods: We systematically searched eight electronic databases from inception to July 2023. We used Assessment of Multiple Systematic Reviews 2 to evaluate the methodological quality, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 to assess report quality, Risk of Bias in Systematic Review to assess the risk of bias, and Grading of Recommendations Assessment, Development, and Evaluation to rate the quality of evidence. Outcome: A total of 36 systematic reviews were included. Our results were classified as clear evidence of benefit: hospitalization for heart failure; possible benefit: cardiovascular death (mortality) and renal outcome composite; clear evidence of no effect or equivalence: atrial arrhythmias, ventricular arrhythmia, atrial fibrillation, and hypotension; possible harm: genital infection; insufficient evidence to draw a conclusion: atrial flutter, major adverse cardiovascular events, urinary tract infection, acute kidney injury, hypoglycemia, and bone fracture. Conclusions: Sodium-dependent glucose transporter 2 inhibitors are beneficial for the treatment of heart failure, especially in terms of heart failure hospitalization.<\/jats:p>","DOI":"10.3390\/jcdd11070198","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T08:31:36Z","timestamp":1719563496000},"page":"198","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sodium\u2013Glucose Transporter 2 Inhibitors in Heart Failure: An Overview of Systematic Reviews"],"prefix":"10.3390","volume":"11","author":[{"given":"Yixuan","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Endocrinology & Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"Innovation Center for Wound Repair, Diabetic Foot Care Center, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"Innovation Center for Wound Repair, Diabetic Foot Care Center, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"Innovation Center for Wound Repair, Diabetic Foot Care Center, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-1241","authenticated-orcid":false,"given":"Xingwu","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China"},{"name":"Innovation Center for Wound Repair, Diabetic Foot Care Center, West China Hospital, Sichuan University, Chengdu 610041, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjcard.2019.10.024","article-title":"Heart Failure and Diabetes Mellitus: Defining the Problem and Exploring the Interrelationship","volume":"124","author":"Wilkinson","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global Public Health Burden of Heart Failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card. Fail. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11886-021-01588-y","article-title":"Improving Quality of Life in Heart Failure","volume":"23","author":"Freedland","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease. The Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2337\/dc17-2583","article-title":"Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction","volume":"41","author":"Jhund","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pcad.2019.07.003","article-title":"Diabetes, heart failure, and renal dysfunction: The vicious circles","volume":"62","author":"Braunwald","year":"2019","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial","volume":"77","author":"Packer","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1253\/circrep.CR-19-0049","article-title":"Rationale and Design of the CANONICAL Study\u2014Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus","volume":"1","author":"Kasama","year":"2019","journal-title":"Circ. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: A Review in Type 2 Diabetes","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijcard.2022.11.052","article-title":"Efficacy of SGLT2 inhibitors in patients with heart failure: An overview of systematic reviews","volume":"377","author":"Sephien","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s10741-023-10324-3","article-title":"Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: An overview of 36 systematic reviews","volume":"28","author":"Karakasis","year":"2023","journal-title":"Heart Fail. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Li, R., Dai, G., Guan, H., Gao, W., Ren, L., Wang, X., and Qu, H. (2023). Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: An umbrella review of systematic reviews and meta-analyses. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1143658"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.rehab.2019.12.008","article-title":"Tai Chi for improving balance and reducing falls: An overview of 14 systematic reviews","volume":"63","author":"Zhong","year":"2020","journal-title":"Ann. Phys. Rehabil. Med."},{"key":"ref_22","first-page":"Cd012394","article-title":"Interventions to prevent women from developing gestational diabetes mellitus: An overview of Cochrane Reviews","volume":"6","author":"Griffith","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/BRS.0b013e318145308d","article-title":"Introduction to and techniques of evidence-based medicine","volume":"32","author":"Fisher","year":"2007","journal-title":"Spine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","article-title":"ROBIS: A new tool to assess risk of bias in systematic reviews was developed","volume":"69","author":"Whiting","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1111\/dom.14470","article-title":"Sodium-glucose cotransporter-2 inhibitors for type 2 diabetes mellitus in adults: An overview of 46 systematic reviews","volume":"23","author":"Augusto","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_29","first-page":"854","article-title":"Efficacy and safety of dapagliflozin for heart failure","volume":"37","author":"Wang","year":"2021","journal-title":"J. Clin. Cardiol."},{"key":"ref_30","first-page":"e29896","article-title":"A Systematic Review Exploring the Cardiovascular and Renal Effects of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction","volume":"14","author":"Athiyaman","year":"2022","journal-title":"Cureus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1097\/MJT.0000000000001452","article-title":"Sodium-Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients with Heart Failure: Evidence From a Meta-Analysis of Randomized Trials","volume":"29","author":"Camilli","year":"2021","journal-title":"Am. J. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/ehjqcco\/qcab072","article-title":"Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: A systematic review and meta-analysis of randomized trials","volume":"8","author":"Ahmad","year":"2022","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e625","DOI":"10.1016\/j.amjmed.2020.04.006","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials","volume":"133","author":"Kumar","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/ehf2.13805","article-title":"Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: A meta-analysis","volume":"9","author":"Pandey","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_35","first-page":"101103","article-title":"Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials","volume":"42","author":"Fukuta","year":"2022","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-023-01860-1","article-title":"Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: A systematic review","volume":"22","author":"Ouyang","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"851","DOI":"10.7326\/M21-4284","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure: A Systematic Review and Meta-analysis","volume":"175","author":"Zou","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/FJC.0000000000001099","article-title":"Sodium-glucose cotransporter-2 Inhibitors in Heart Failure: An Updated Systematic Review and Meta-analysis of 13 Randomized Clinical Trials Including 14,618 Patients With Heart Failure","volume":"78","author":"Shrestha","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/ehf2.13905","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart failure: An updated meta-analysis","volume":"9","author":"Cao","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101597","DOI":"10.1016\/j.cpcardiol.2023.101597","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"48","author":"Ismayl","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/ejhf.2584","article-title":"Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: A systematic review and meta-analysis","volume":"24","author":"Abdin","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"ref_43","first-page":"915","article-title":"A meta-analysis of the efficacy and safety of SGLT2 inhibitors in the treatment of heart failure with reduced ejection fraction","volume":"14","author":"Wu","year":"2022","journal-title":"Chin. J. Evid. Based Cardiovasc. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/jce.15894","article-title":"SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta-analysis of randomized clinical trials","volume":"34","author":"Oates","year":"2023","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100933","DOI":"10.1016\/j.eclinm.2021.100933","article-title":"SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis","volume":"36","author":"Cardoso","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijcard.2022.06.059","article-title":"Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis","volume":"366","author":"Younes","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9927533","DOI":"10.1155\/2021\/9927533","article-title":"The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis","volume":"2021","author":"Tsampasian","year":"2021","journal-title":"Cardiol. Res. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Treewaree, S., Kulthamrongsri, N., Owattanapanich, W., and Krittayaphong, R. (2023). Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1046194"},{"key":"ref_50","first-page":"783","article-title":"Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: A meta-analysis of randomized clinical trials","volume":"18","author":"Bazoukis","year":"2021","journal-title":"J. Geriatr. Cardiol. JGC"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2459\/JCM.0000000000001504","article-title":"Efficacy of SGLT2-inhibitors across different definitions of heart failure with preserved ejection fraction","volume":"24","author":"Savarese","year":"2023","journal-title":"J. Cardiovasc. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/ehf2.13169","article-title":"Efficacy and safety of SGLT2 inhibitors in heart failure: Systematic review and meta-analysis","volume":"7","author":"Butler","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijcard.2021.03.077","article-title":"Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials","volume":"332","author":"Li","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40256-020-00441-x","article-title":"Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis","volume":"21","author":"Zheng","year":"2021","journal-title":"Am. J. Cardiovasc. Drugs Drugs Devices Other Interv."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Zhai, M., Du, X., Liu, C., and Xu, H. (2021). The Effects of Dapagliflozin in Patients With Heart Failure Complicated With Type 2 Diabetes: A Meta-Analysis of Placebo-Controlled Randomized Trials. Front. Clin. Diabetes Healthc., 2.","DOI":"10.3389\/fcdhc.2021.703937"},{"key":"ref_56","first-page":"100690","article-title":"Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis","volume":"32","year":"2021","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zhou, H., Peng, W., Li, F., Wang, Y., Wang, B., Ding, Y., Lin, Q., Zhao, Y., Pan, G., and Wang, X. (2022). Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.875327"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejim.2021.03.020","article-title":"Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials","volume":"87","author":"Lu","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6657380","DOI":"10.1155\/2021\/6657380","article-title":"Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis","volume":"2021","author":"Cai","year":"2021","journal-title":"Cardiol. Res. Pract."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Chen, X., Wang, L., Li, H., Huang, W., Huang, S., Zhao, L., and Guo, W. (2022). Clinical benefit of sodium-glucose transport protein-2 inhibitors in patients with heart failure: An updated meta-analysis and trial sequential analysis. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.1067806"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.dsx.2021.01.006","article-title":"Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Gager, G.M., Gelbenegger, G., Jilma, B., von Lewinski, D., Sourij, H., Eyileten, C., Filipiak, K., Postula, M., and Siller-Matula, J.M. (2021). Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.691907"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"109871","DOI":"10.1016\/j.diabres.2022.109871","article-title":"Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis","volume":"187","author":"Zhao","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10741-022-10281-3","article-title":"Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation\/atrial flutter in heart failure patients with reduced ejection fraction: A meta-analysis of randomized controlled trials","volume":"28","author":"Sfairopoulos","year":"2023","journal-title":"Heart Fail. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics","volume":"73","author":"Ishikawa","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats","volume":"18","author":"Lee","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12933-020-01163-9","article-title":"Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk","volume":"19","author":"Giorgino","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4070\/kcj.2017.0030","article-title":"Current Drug Therapy in Chronic Heart Failure: The New Guidelines of the European Society of Cardiology (ESC)","volume":"47","author":"Berliner","year":"2017","journal-title":"Korean Circ. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int. Rep."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/11\/7\/198\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:07:00Z","timestamp":1760108820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/11\/7\/198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":71,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["jcdd11070198"],"URL":"https:\/\/doi.org\/10.3390\/jcdd11070198","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}